Mosapride, a selective serotonin 5-HT4 receptor agonist, and alogliptin, a selective dipeptidyl peptidase-4 inhibitor, exert synergic effects on plasma active GLP-1 levels and glucose tolerance in mice

Katsunori Nonogaki; Takao Kaji

doi:10.1016/j.diabres.2015.10.011

Mosapride, a selective serotonin 5-HT4 receptor agonist, and alogliptin, a selective dipeptidyl peptidase-4 inhibitor, exert synergic effects on plasma active GLP-1 levels and glucose tolerance in mice

Katsunori Nonogaki, Takao Kaji

New Industry Creation Hatchery Center (NICHe)

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Pharmacologic stimulation of serotonin 5-HT4 receptors increased plasma active glucagon-like-peptide-1 (GLP-1) levels independent of feeding, and that pharmacologic stimulation of 5-HT4 receptors and pharmacologic inhibition of dipeptidyl peptidase-4 exerted synergic effects on plasma active GLP-1 levels and glucose tolerance in mice.

Original language	English
Pages (from-to)	e18-e21
Journal	Diabetes Research and Clinical Practice
Volume	110
Issue number	3
DOIs	https://doi.org/10.1016/j.diabres.2015.10.011
Publication status	Published - 2015 Dec 1

Keywords

5-HT4 receptor agonist
Alogliptin
DPP-4 inhibitor
GLP-1
Glucose tolerance
Mosapride

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Endocrinology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.diabres.2015.10.011

Cite this

Mosapride, a selective serotonin 5-HT4 receptor agonist, and alogliptin, a selective dipeptidyl peptidase-4 inhibitor, exert synergic effects on plasma active GLP-1 levels and glucose tolerance in mice. / Nonogaki, Katsunori ; Kaji, Takao.

In: Diabetes Research and Clinical Practice, Vol. 110, No. 3, 01.12.2015, p. e18-e21.

Research output: Contribution to journal › Article › peer-review

@article{21e9393cf30e4f74b4d44e35fcf04a89,

title = "Mosapride, a selective serotonin 5-HT4 receptor agonist, and alogliptin, a selective dipeptidyl peptidase-4 inhibitor, exert synergic effects on plasma active GLP-1 levels and glucose tolerance in mice",

abstract = "Pharmacologic stimulation of serotonin 5-HT4 receptors increased plasma active glucagon-like-peptide-1 (GLP-1) levels independent of feeding, and that pharmacologic stimulation of 5-HT4 receptors and pharmacologic inhibition of dipeptidyl peptidase-4 exerted synergic effects on plasma active GLP-1 levels and glucose tolerance in mice.",

keywords = "5-HT4 receptor agonist, Alogliptin, DPP-4 inhibitor, GLP-1, Glucose tolerance, Mosapride",

author = "Katsunori Nonogaki and Takao Kaji",

year = "2015",

month = dec,

day = "1",

doi = "10.1016/j.diabres.2015.10.011",

language = "English",

volume = "110",

pages = "e18--e21",

journal = "Diabetes Research and Clinical Practice",

issn = "0168-8227",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

TY - JOUR

T1 - Mosapride, a selective serotonin 5-HT4 receptor agonist, and alogliptin, a selective dipeptidyl peptidase-4 inhibitor, exert synergic effects on plasma active GLP-1 levels and glucose tolerance in mice

AU - Nonogaki, Katsunori

AU - Kaji, Takao

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Pharmacologic stimulation of serotonin 5-HT4 receptors increased plasma active glucagon-like-peptide-1 (GLP-1) levels independent of feeding, and that pharmacologic stimulation of 5-HT4 receptors and pharmacologic inhibition of dipeptidyl peptidase-4 exerted synergic effects on plasma active GLP-1 levels and glucose tolerance in mice.

AB - Pharmacologic stimulation of serotonin 5-HT4 receptors increased plasma active glucagon-like-peptide-1 (GLP-1) levels independent of feeding, and that pharmacologic stimulation of 5-HT4 receptors and pharmacologic inhibition of dipeptidyl peptidase-4 exerted synergic effects on plasma active GLP-1 levels and glucose tolerance in mice.

KW - 5-HT4 receptor agonist

KW - Alogliptin

KW - DPP-4 inhibitor

KW - GLP-1

KW - Glucose tolerance

KW - Mosapride

UR - http://www.scopus.com/inward/record.url?scp=84955184711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955184711&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2015.10.011

DO - 10.1016/j.diabres.2015.10.011

M3 - Article

C2 - 26497774

AN - SCOPUS:84955184711

VL - 110

SP - e18-e21

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 3

ER -

Mosapride, a selective serotonin 5-HT4 receptor agonist, and alogliptin, a selective dipeptidyl peptidase-4 inhibitor, exert synergic effects on plasma active GLP-1 levels and glucose tolerance in mice

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this